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AbstrAct
Objective The present study aimed to evaluate the 
association between smoking and incident pterygium in 
adult Korean men.
Design A retrospective nationwide longitudinal cohort.
setting National Health Insurance database of South 
Korea.
Participants This study included Korean men (age range: 
40–79 years) registered in the Korea National Health 
Insurance Service database from 2002 through 2013. We 
compared HRs for pterygium between 90 547 current/past 
and 90 547 never-smokers via 1:1 propensity-matched 
analysis.
Primary outcome measure Incident cases of pterygium 
were identified from the database.
results Pterygium developed in 5389 (6.0%) never-
smokers and 3898 (4.3%) past/current smokers 
(P<0.001). The incidence of pterygium per 1000 person-
years in never-smokers and in past/current smokers was 
6.5 and 4.7, respectively (age-adjusted HR, 0.73; 95% CI, 
0.70 to 0.76). This protective effect was more pronounced 
among current smokers than among past smokers (for 
current smokers: HR, 0.68; 95% CI, 0.65 to 0.71 and for 
past smokers: HR, 0.85; 95% CI, 0.80 to 0.90). A longer 
duration of smoking and higher amounts of cigarette 
consumption were associated with a lower incidence of 
pterygium.
conclusions Longitudinally, cigarette smoking was 
associated with a reduced risk of pterygium, and this 
protective effect was more pronounced among current 
smokers than among past smokers.
IntrODuctIOn
Cigarette smoking is considered one of the 
most important risk factors for a number of 
systemic diseases1 and eye diseases such as 
age-related macular degeneration,2 retinal 
vein occlusion3 and thyroid eye disease.4 
However, for some diseases or conditions, 
inverse association was also reported: 
smoking seemed to relieve inflammatory 
bowel disease5; smoking was associated with 
decreased incidence of Parkinson disease6 
and smokers seemed to have better short-term 
health outcomes than non-smokers following 
hospitalisation for heart attacks, a phenom-
enon also known as ‘smoker’s paradox’ in 
cardiology.7 8
Pterygium is a triangular mass of thick-
ened conjunctiva extending over the cornea 
that may cause a disturbance in vision. The 
association between smoking and pterygium 
has been investigated via cross-sectional 
studies,9–21 a propensity score-matched study22 
and meta-analysis.23 Unlike most reports on 
the negative aspects of smoking in public 
health and the majority of systemic diseases, 
smoking has been repeatedly reported as a 
protective factor against the development 
of pterygium in cross-sectional studies,13–16 
including one conducted in Korea.21
However, to establish a temporal rela-
tionship between cigarette smoking and 
the development of pterygium, a large, 
well-designed longitudinal cohort study is 
required. The National Health Insurance 
Service (NHIS) database in South Korea 
provides an adequate opportunity for the 
evaluation of the development of pterygium 
among the general population according 
to smoking status. Therefore, we evaluated 
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Research
strengths and limitations of this study
 ► This study is unique because our study is the first 
large-scale longitudinal study to evaluate the 
temporal relationship between cigarette smoking 
and risks of pterygium.
 ► A lack of clinical information, including visual acuity, 
severity of pterygium and the eye affected, is an 
inherent limitation of the present claims database 
study.
 ► Last, we could not access data on sun exposure, 
which is one of the most important risk factors for 
pterygium. However, our detailed stratified matching 
allowed us to establish two comparable groups and 
eliminated the effect of confounding factors, such as 
sun exposure.
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Figure 1 Flow chart of participant selection.
the association between cigarette smoking and incident 
pterygium in a nationwide random sample comprising 
181 094 men from South Korea.
MethODs
ethics
This retrospective cohort study adhered to the tenets of 
the Declaration of Helsinki, and the study design was 
approved by the institutional review board of the NHIS 
Ilsan Hospital, which waived the requirement for written 
informed consent.
Database
A unique national insurance system has been imple-
mented in South Korea, covering approximately 97% of 
the nation’s population. This study used a new dataset 
developed by the Korean NHIS and released for use in 
research for the first time in 2016: the National Health 
Screening Cohort (NHIS-HEALS).24 The NHID includes 
approximately 510 000 randomly selected individuals 
between the ages of 40–79 years, who were enrolled in 
the Korean National Health Screening Program in 2002 
and 2003 (~10% of NHIS beneficiaries who had partic-
ipated in a screening program). These selected partici-
pants were followed up until 2013. The database contains 
data regarding sociodemographic factors, medical exam-
ination results, interventions, prescription drugs and 
diagnostic codes for all medical care transactions from all 
types of medical facilities. Detailed cohort profiling has 
been described previously.24
study cohort
Based on a previous report regarding the presence of a 
large proportion of unreported women smokers in Korea 
due to cultural and social barriers,25 and because of the very 
low proportion of women smokers (3.9%) in the NHID 
database, we included only men in this study. Therefore, 
the study cohort included men enrolled in the National 
Health Screening Program between 2002 and 2003 who 
met the following eligibility criteria: (1) response to ques-
tions regarding smoking status; (2) age between 40 and 79 
years in 2002 (the lower and upper limits were set based 
on those of the database) and (3) clinical data for contin-
uous variables including body mass index, blood pressure 
and other parameters (except age) within the top and 
bottom 1%. Patients with pterygium in 2002 and 2003 were 
excluded. A detailed diagram of the study population is 
shown in figure 1. We performed propensity matching of 
the study cohort according to propensity scores based on 
38 potential baseline confounders, including age, income 
level, area of residence, medical history and examination 
results, history of prescription-drug use and antihyperten-
sive medication and utilisation of eye care (table 1). Details 
regarding diagnosis codes for comorbidity are provided in 
online supplementary table 1. Sociodemographic factors 
such as income level or residence area were identified as 
one of the strongest predictors for pterygium in previous 
studies.9–21 All Korean citizens were categorised as insured 
employees, insured self-employed individuals or medical 
aid beneficiaries. This database provided subjects’ income 
levels in 10 percentiles for insured employees, 10 percen-
tiles for insured self-employed and the lowest level of 
income for medical aid beneficiaries, in a total of 21 levels. 
However, since the proportion of medical aid beneficiaries 
were very small, we combined the lowest level of 10 percen-
tiles from insured self-employed group and medical aid 
beneficiaries group. Geographically, South Korea could 
be divided into 16 different provinces. Therefore, we strat-
ified income level using a 20-level categorisation and area 
of residence using 16-level categorisation. Korean citizens 
who were covered under NHIS were categorised as insured 
employees, insured self-employed individuals and Medical 
Aid beneficiaries. Income among insured employees was 
categorised into income levels 1–10, while income among 
insured self-employed individuals was categorised into 
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Table 1 Baseline characteristics of the study participants (smokers vs never-smokers matched using propensity score 
matching)
Characteristic
Propensity-score-matched cohort (n=181 094)
Never-smoker cohort 
(n=90 547)
Smoker cohort (past and 
current) (n=90 547) P Value
Pterygium—no. (%) 5389 (6.0) 3898 (4.3) <0.001
Age (years) 52.3±9.2 52.3±9.2 0.338
Body mass index (kg/cm2) 2.6±17.6 24.1±2.6 0.202
Systolic blood pressure (mm Hg) 128.5±16.3 128.5±16.4 0.766
Diastolic blood pressure (mm Hg) 81.1±10.6 81.1±10.5 0.391
Fasting glucose 97.5±22.6 97.6±22.9 0.314
Total cholesterol 198.0±33.8 198.0±33.9 0.981
Haemoglobin 14.8±1.1 14.8±1.1 0.099
Aspartate aminotransferase 27.2±9.5 27.2±9.7 0.495
Alanine transaminase 27.8±14.1 27.7±14.0 0.228
Charlson’s Comorbidity Index 0.5±1.0 0.5±1.0 0.880
Mean number of eye care use in 2002–2003 1.1±0.3 1.1±0.3 0.778
Hypertension—no. (%) 13 229 (14.6) 13 216 (14.6) 0.931
Hyperlipidaemia—no. (%) 4498 (5.0) 4502 (5.0) 0.966
Acute myocardial infarction—no. (%) 336 (0.4) 328 (0.4) 0.756
Heart failure—no. (%) 1974 (2.2) 1967 (2.2) 0.910
Peripheral vascular disease—no. (%) 954 (1.1) 922 (1.0) 0.458
Cerebrovascular disease—no. (%) 1431 (1.6) 1448 (1.6) 0.749
Chronic pulmonary disease—no. (%) 5965 (6.6) 5943 (6.6) 0.835
Liver diseases—no. (%) 5990 (6.6) 5997 (6.6) 0.947
Uncomplicated diabetes—no. (%) 5170 (5.7) 5162 (5.7) 0.935
Complicated diabetes—no. (%) 1585 (1.8) 1592 (1.8) 0.900
Cancer—no. (%) 1372 (1.5) 1343 (1.5) 0.575
Prescription-drug use in 2002–2003—no. (%)
  Antidiabetes mellitus medication
   Metformin 2627 (2.9) 2648 (2.9) 0.769
   Sulfonylurea 3817 (4.2) 3821 (4.2) 0.963
   Meglitinide 128 (0.1) 132 (0.2) 0.804
   Thiazolidinedione 91 (0.1) 85 (0.1) 0.651
   Alpha Glucosidase Inhibitors 1212 (1.3) 1219 (1.4) 0.886
   Insulin 52 (0.1) 52 (0.1) >0.999
  Antihypertensives
   Angiotensin II receptor antagonist 3599 (4.0) 3573 (4.0) 0.754
   Angiotensin-converting-enzyme inhibitor 6762 (7.5) 6814 (7.5) 0.643
   Calcium channel blocker 11 807 (13.0) 11 770 (13.0) 0.796
   Diuretics 7625 (8.4) 7600 (8.4) 0.832
   Beta-blocker 7685 (8.5) 7666 (8.5) 0.873
   Others 1050 (1.2) 1032 (1.1) 0.692
  Statins 3647 (4.0) 3626 (4.0) 0.802
  Aspirin 1851 (2.0) 1877 (2.1) 0.667
Comparisons were made using t-tests and χ²-square tests for continuous and for categorical variables, respectively.
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Table 2 Incidence of pterygium in smokers and non-smokers
Analysis
Propensity-score-matched cohort (n=181 094)
Never smokers (n=90 547) Smokers (past and current) (n=90 547)
Primary analysis
  Total follow-up (PYs) 826 493 823 592
  No. of pterygium 5389 3898
  Incidence (no./1000 PYs, 95% CI) 6.5 4.7
  Age-adjusted HR (95% CI) 1 (reference) 0.73 (0.70 to 0.76)
  P Value <0.001
Subgroup analysis
Age 40–59 years
   Total follow-up (PYs) 641 801 642 005
   No. of pterygium 3874 2717
   Incidence (no./1000 PYs, 95% CI) 6.0 4.2
   Age-adjusted HR (95% CI) 1 (reference) 0.70 (0.67 to 0.74)
   P Value <0.001
Age 60–79 years
   Total follow-up (PYs) 184 692 181 587
   No. of pterygium 1515 1181
   Incidence (no./1000 PYs, 95% CI) 8.2 6.5
   Age-adjusted HR (95% CI) 1 (reference) 0.79 (0.73 to 0.85)
   P Value <0.001
 PYs, person-years.
income levels 11–20. Income among Medical Aid beneficia-
ries was categorised as income level 1.
smoking status and validation
The Korean National Health Screening Program 
employed a standardised questionnaire for smoking 
status (see online supplementary document 1). Partic-
ipants were classified according to smoking status as 
never-smokers or smokers. Smokers were classified as 
either past or current smokers. For subgroup analyses, 
we also collected data regarding the duration of smoking 
(≤9, 10–29 or ≥30 years) and daily cigarette consumption 
(<10, 10–19, 20–29 or ≥30 cigarettes).
To verify the smoking status of self-reported never-
smokers during 2008–2013, we determined the propor-
tion of men who had reported being current or past 
smokers during 2002–2007. A total of 61 210 men had 
reported being never-smokers more than once during 
2008–2013, of whom 47 178 (77.1%) had reported being 
never-smokers more than once during 2002–2007 as well. 
Therefore, smoking status was largely consistent over 
time.26
Follow-up and primary end points
Participants enrolled between 2002 and 2003 were 
followed up from 1 January 2004 until the first date on 
which one of the following had occurred: loss to follow-up 
due to disqualification from NHIS (mainly death), inci-
dence of pterygium in any eye or last visit to any medical 
care facility within the study period (31 December 2013). 
The primary end-point of the study was the incidence of 
pterygium. Cases of pterygium were defined based on 
an ophthalmologist’s examination and claims with the 
Korean Classification of Diseases code for pterygium 
(H110; corresponding to 372.4 from the International 
Classification of Diseases, Ninth Revision, Clinical Modi-
fication). Incident pterygium was defined based on the 
person rather than based on the eye.27 We defined an 
incident case as the first diagnosis of pterygium in any eye 
regardless of the right or left side of the eye.
statistical analysis
We developed propensity models using logistic regres-
sion for smokers (past and current) compared with 
never-smokers. Individual propensities for smokers were 
estimated via logistic regression analysis of 38 potential 
confounders (table 1). Smokers and never-smokers were 
then matched according to propensity scores in a 1:1 ratio 
based on 8→1 digit matching. We performed descrip-
tive statistical analysis of propensity-matched cohorts to 
estimate the incidence of pterygium per 1000 person-
years. Cox regression models were used to estimate HRs. 
Data of the propensity-matched cohort were evaluated 
via age-adjusted analysis. The cumulative incidence of 
pterygium from 1 January 1 2004 to 31 December 2013 
was described using a Kaplan–Meier survival curve. Cox 
proportional hazards analysis of the duration of smoking 
 5Rim TH, et al. BMJ Open 2017;7:e017014. doi:10.1136/bmjopen-2017-017014
Open Access
Figure 2 Cumulative incidence of pterygium among smokers and never-smokers between 1 January 2004 and 31 December 
2013. We observed significant differences in the cumulative incidence of pterygium between smokers and never-smokers 
included in a retrospective cohort derived from a National General Health Screening Program conducted between 2002 and 
2013 (A and B).
Table 3 Incidence of pterygium in smokers and non-smokers 
Propensity-score-matched analysis (n=181 094)
Never-smoker Smoker
(n=90 547) Past smoker (n=26 152) Current smoker (n=64 395)
Total follow-up (PYs) 826 493 238 697 584 895
No. of pterygium 5389 1342 2556
Incidence (no./1000 PYs, 95% CI) 6.5 5.6 4.4
Age-adjusted HR (95% CI) 1 (reference) 0.85 (0.80 to 0.90) 0.68 (0.65 to 0.71)
P Value <0.001 <0.001
P for trends <0.001
PYs, person-years.
was performed according to 1-year age strata in order to 
account for immortal-time bias. The association between 
daily cigarette consumption and pterygium was evaluated 
via age-adjusted analysis. Proportional-hazard assump-
tion for Cox regression was verified using the plot of 
log (-log); graphs showed no indication of violation. For 
sensitivity analysis, data of the whole cohort were evalu-
ated via propensity-adjusted analysis according to deciles 
of propensity scores and age. The level of statistical signif-
icance was set at P<0.05. Analyses were performed using 
SAS System for Windows V.9.4 (SAS Institute, Cary, North 
Carolina, USA) and Stata/MP V.14.0 (StataCorp, College 
Station, Texas, USA).
results
characteristics of the study cohort
A total of 181 094 men met the inclusion criteria, 
including 90 547 never-smokers and 90 547 past/current 
smokers (table 1). Patient demographic and clinical char-
acteristics in the whole unmatched cohort (n=229 493) 
varied greatly between the two groups; these data are 
provided in online supplementary table 2. In the propen-
sity-matched cohort, all variables, except the incidence 
of pterygium, were similar between the two cohorts: 
pterygium developed in 5389 never-smokers and 3898 
smokers (P<0.001). Detailed comparisons between the 
two groups based on the 20 income strata and 16 area 
of residence strata are provided in online supplemen-
tary table 3. Income and area of residence were similar 
between the two groups.
Incidence of pterygium
Table 2 presents the HRs for pterygium for the propen-
sity score-matched cohorts. The risk of pterygium among 
smokers was significantly lower than among never-
smokers in propensity-matched cohorts (age-adjusted 
HR, 0.73; 95% CI, 0.70 to 0.76). The risk of pterygium 
in age subgroups (40–59 and 60–79 years) exhibited a 
similar trend; however, HRs for the older age-subgroup 
were greater than those for the younger age-subgroup 
(HR: younger cohort, 0.70; older cohort, 0.79). The 
Kaplan–Meier survival curve demonstrated a clear differ-
ence in the incidence of pterygium between smokers and 
never-smokers (figure 2A).
In table 3, HRs for past smokers were lower than those 
for never-smokers and greater than those for current 
smokers in the age-adjusted model (HR: past smokers, 
0.85; current smokers, 0.68). This trend was also reflected 
in the survival curve for the cumulative incidence of 
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Table 4 HRs and 95% CIs for pterygium according to duration and frequency of smoking
Smoking status No. of cases Crude % HR 95% CI P Value
Duration of smoking (n=181 094)
  Never smoked 5389/90 547 5.93 1 (reference)
  ≤9 years 503/10 835 4.68 0.81 0.74 to 0.89 <0.001
  10–19 years 837/22 625 3.69 0.69 0.64 to 0.74 <0.001
  20–29 years 1133/28 937 3.78 0.70 0.65 to 0.74 <0.001
  ≥30 years 1425/28 150 5.05 0.75 0.71 to 0.80 <0.001
Daily consumption of cigarette (n=154 942)
  Never smoked 5389/90 547 5.98 1 (reference)
  <10 cigarettes 670/15 791 4.73 0.69 0.64 to 0.75 <0.001
  10–19 cigarettes 1342/34 533 3.68 0.67 0.63 to 0.71 <0.001
  ≥20 cigarettes 544/14 071 3.65 0.68 0.62 to 0.74 <0.001
We performed age-stratified analyses for the duration of smoking and pterygium as well as age-adjusted analyses for daily consumption of 
cigarettes and pterygium. Persons with missing data regarding daily cigarette consumption were excluded.
pterygium: the survival curve of past smokers was located 
between those of never-smokers and current smokers 
(figure 2B).
Table 4 shows subgroup analyses of smoking for the risk 
of pterygium. In the 1-year age-stratified Cox model, men 
who smoked for 10–19, 20–29 and ≥30 years were less 
likely to have pterygium than never-smokers (HR, 0.69, 
0.70 and 0.75, respectively). Similar negative association 
was observed in terms of daily cigarette consumption: 
men who smoked <10, 10–19 and ≥20 cigarettes daily were 
less likely to have pterygium than never-smokers (HR, 
0.69, 0.67 and 0.68, respectively). In sensitivity analyses 
of the unmatched cohort using propensity score-adjusted 
analysis, the multivariable-adjusted HR for pterygium for 
smokers was 0.72 (95% CI, 69 to 0.75) (see online supple-
mentary table 4).
DIscussIOn
To our knowledge, our study is the first large-scale longitu-
dinal study to evaluate the temporal relationship between 
cigarette smoking and risks of pterygium in a nationwide 
sample of 181 094 Korean men. We confirmed the protec-
tive effect of smoking against the prospective development 
of pterygium in a historical cohort. This effect was more 
pronounced in current smokers than in past smokers and 
was surprisingly greater in men who smoked more than 
in those who smoked less. Our results are noteworthy 
because various conditions were controlled, including 
age, income level, area of residence, health examination 
variables, comorbidities, drug use and frequency of eye 
care utilisation.
Previous cross-sectional studies have reported incon-
sistent results regarding the prevalence of pterygium in 
individuals who smoke. Among the Chinese population 
in Singapore, smoking was associated with a higher risk of 
pterygium in univariate analysis; however, in a model with 
age, sex, occupation and smoking as covariates, no such 
association was observed.17 Among the Malay population 
in Singapore, bilateral pterygium was marginally associ-
ated with smoking (OR, 1.5; 95% CI, 1.0 to 2.2). However, 
no type of pterygium (in one eye or both eyes) was 
significantly associated with smoking (OR, 1.2; 95% CI, 
0.9 to 1.5).11 Similarly, a more recent pooled analysis of 
the three major ethnic groups in Singapore revealed no 
significant association between smoking and pterygium/
severe pterygium.20 In a previous cross-sectional study 
conducted in South Korea,21 analyses revealed somewhat 
different results depending on the method used to control 
for other variables, such as sociodemographic factors: 
in unadjusted analyses, longer duration of smoking was 
associated with an increased risk of pterygium; however, 
in adjusted analyses including sociodemographic factors 
and sun exposure as factors, the opposite finding was 
observed. Finally, in a multivariable model, lifetime 
smokers had a lower prevalence of pterygium compared 
with never-smokers (OR, 0.7; 95% CI, 0.6 to 0.9). This also 
highlights the importance of proper control for other 
sociodemographic factors in a cross-sectional study.21
The Barbados Eye Study, which included a predom-
inantly African Caribbean population living in an area 
with very different climate and race compared with the 
above-mentioned Asian countries, also reported the 
protective effect of smoking on pterygium. However, an 
early cross-sectional study performed in 2001 reported 
a low prevalence of pterygium among current smokers 
(OR, 0.62; 95% CI, 0.41 to 0.94),13 while a later longitu-
dinal study reported a relatively weaker protective effect 
(OR, 0.82; 95% CI, 0.48 to 1.39).28
The mechanism underlying the protective effect of 
smoking on pterygium remains somewhat unclear. Such 
effects may be explained by vasoconstriction or suppres-
sion of inflammatory cytokines induced by nicotine as well 
as alterations in the tear film such as increases in levels 
of secreted antibodies. However, as our epidemiological 
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study could not provide any evidence regarding this 
matter, further studies are required to more fully eluci-
date the mechanism underlying the development of 
pterygium.
This study has several limitations. First, we had no 
access to data on the severity of pterygium or the eye 
affected (right, left or both). Second, it is possible 
that self-reported smoking habits are underestimated. 
However, this misclassification bias would lead to 
the underestimation of the true association between 
smoking and pterygium. However, it is possible that 
delayed diagnosis resulted in underestimation of 
pterygium incidence in the present study. Third, we 
also considered the possibility that the study popula-
tion included in the health screening databases may 
have been biased relative to general population-based 
controls, who may not have received national general 
health screening. it is also possible that these biases were 
similar among smokers and never-smokers. To mini-
mise selection or surveillance bias, we controlled for 38 
possible confounding factors, including eye care utilisa-
tion. To minimise the immortal time bias, we performed 
a 1-year age-stratified analysis to estimate the association 
between duration of smoking and pterygium. Fourth, we 
could not access data on sun exposure, which is one of 
the most important risk factors for pterygium. However, 
we performed a detailed stratified matching of sociode-
mographic factors, including 20 strata for income level 
and 16 strata for area of residence, between smokers and 
never-smokers. This stratified matching allowed us to 
establish two comparable groups while eliminating the 
effect of confounding factors such as sun exposure. In 
addition, our results should be generalised with some 
caution, as this study was limited to East Asian men only.
In conclusion, our longitudinal study revealed a 
temporal relationship between cigarette smoking and 
subsequent lower incidence of pterygium. This protec-
tive effect was more pronounced among current smokers 
than among past smokers. We also found a low risk of 
pterygium in smokers, after dividing smoking by duration 
or intensity. Unlike the negative aspects of smoking in 
public health and various diseases, cigarette smoking may 
have an unexpected protective effect on the development 
of pterygium.
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